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Abstract 
BACKGROUND: Mutations causing p53 inactivation are among the most common genetic alterations in human 
malignant tumours including hepatocellular carcinoma. Detection of p53 gene mutations in patients with 
hepatocellular carcinoma (HCC) should provide relevant data for the patients from the Republic of Macedonia and 
should allow the survivals additional therapeutic option as is gene therapy. 
AIM: We aimed to detect p53 gene mutations in HCC tissue, and to correlate them with the immunoexpression of 
p53 protein and multiple clinicopathologic characteristics of a tumour. 
MATERIAL AND METHODS: We analysed thirty patients with HCC for multiple clinic-pathological characteristics. 
Tumour tissue samples were immunostained for p53 and detection of p53 gene mutations was performed by 
polymerase chain reaction followed by Sanger sequencing. 
RESULTS: Changes in p53 gene sequence were detected in four patients (13.33%), one of them a polymorphism 
and the other three were missense point mutations with p53 immunoexpression of 50%, 0%, 0% and 90%, 
respectively. All patients with p53 mutations had cirrhosis. Two of them had Hepatitis B infection, moderately 
differentiated tumour and T2 status. There was one case with a well-differentiated tumour and one with T4 status. 
All of them were with vascular invasion. The size of the tumours was in the range of 2.5 cm to 16 cm. All 3 
mutations were located in exon 7. 
CONCLUSION: Mutations in p53 gene are not always associated with obviously altered immunoexpression of 
p53 protein. Detection of p53 gene mutations is necessary in each case because the new therapeutic modalities 
offer to apply gene therapy.  
 
 
 
 
 
 
 
 
Introduction 
 
Tumour suppressor gene p53 plays a key role 
in cell cycle regulation, cell proliferation and apoptosis 
following DNA damage. p53 is responsible for 
maintenance of genomic integrity [1] [2]. Inactivation 
mutation of p53 is among the most common genetic 
alterations in human cancers, including hepatocellular 
carcinoma (HCC). The mutational spectrum of p53 
gene differs in HCC from different geographic regions. 
This difference comes due to differences in population 
exposition to Aflatoxin B1 and Hepatitis B infection 
(HBV). Transversion of guanine to thymine at the third 
position of codon 249 is a common finding in patients 
with HCC from southern Africa and southern China 
[2]. 
In contrast, in regions where exposure to 
Aflatoxin B1 is low, there are almost no mutations in 
codon 249, or they occur less significantly [2] [3] [4] [5] 
[6] [7]. Population in the Republic of Macedonia is 
exposed to Hepatitis B infection with the incidence of 
7.8 in the 2013 year [8], and the same year Aflatoxin 
M1and B1 contamination is found in raw milk and feed 
[9]. In the neighbouring countries, the contamination 
of raw milk with Aflatoxin Ma and B1 was detected 
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earlier [10]. According to EUROCAN the incidence 
rate of liver cancer and intrahepatic bile duct cancer in 
the Republic of Macedonia is 8.4, and the mortality 
rate is 11.1 [11]. 
Mutations of p53 gene or positive 
immunostaining for mutated p53 protein can be used 
as a significant indicator of poor prognosis in patients 
with HCC [12] [13]. Modern therapeutic possibilities 
such as surgical resection, liver transplantation, 
percutaneous ablation and transcatheter 
chemoembolization provide a better prognosis for 
patients, but the overall survival rate in patients with 
HCC remains low [11]. Hence, great importance for 
patients with HCC is the development of 
multidisciplinary interventions and new therapeutic 
approaches, including biotherapy. The efficacy of 
chemo and radiotherapy may be elevated by an 
endogenous or exogenous normal type of p53. There 
are currently several in vitro and in vivo studies with 
products for modulating the p53 status [14]. 
Advexin (for adenoviral p53), ONYX-015, 
CNHK200, SCH58500 are products in clinical 
development, while Gendicine-a gene therapy product 
mainly built from normal p53 and modified adenovirus 
is already approved for commercial use by the 
Chinese State Food and Drugs Administration [15] 
[16] [17] [18] [19]. Due to the new therapeutic 
possibilities, and because the presence of the mutant 
p53 gene in HCC is an indicator of a poor prognosis, 
the detection of the mutant gene and the presence of 
its protein are extremely important for patients with 
HCC. 
This study aims to determine the mutations of 
the p53 gene and correlate them with the 
immunohistochemical expression of its product, as 
well as to correlate them with the clinical and 
pathological characteristics of a tumour in 30 cases of 
HCC in patients from the Republic of Macedonia. 
 
 
Material and Methods 
 
We analysed 30 patients with histologically 
proven HCC, diagnosed and treated at the University 
Clinic of Gastroenterology and Hepatology and the 
University Clinic of Abdominal Surgery in Skopje 
Following parameters were determined by 
echosonography and computed tomography images: 
the dimension of tumour node, the multiplicity of the 
tumour nodes, the presence of tumour emboli in the 
large vessels and the presence of cirrhosis in the 
surrounding liver tissue. Serological tests for hepatitis 
B and C infection were performed in all patients. All 
patients were followed up until the death. 
During the diagnostic procedure of HCC at 
the Institute of Pathology in Skopje, the grade of 
differentiation, vascular invasion, T category of pTNM 
classification (AJCC 2017) and the presence of 
cirrhosis in the surrounding, peritumoral liver tissue 
was determined. Additionally, immunohistochemical 
staining for p53 and PCR for the detection of p53 
gene mutations were performed. 
Immunohistochemical stainings with an 
antibody against p53 (Monoclonal Mouse, Anti-
Human, Clone DO-7, DACO, dilution 1:50) using 
Avidin-Biotin immunoperoxidase technique were 
made. For the visualisation of the antigen-antibody 
reaction, LSAB and En-Vision kit from DAKO was 
used. The results of immunostaining were determined 
as a percentage of positive nuclear signals for p53. 
For the determination of p53 gene mutation 
polymerase chain reaction (PCR) with subsequent 
Sanger sequencing of exons 2-11 of the p53 gene 
were performed. The primers for each exon are 
shown in Table 1. 
Table 1: Nucleotide sequences of primers used for 
amplification (p53 priming sequences) 
Oligonucleotide Oligo sequence (5' to 3') Product size 
p53Ex2-3F tctcatgctggatccccact 365 
P53Ex2-3R agtcagaggaccaggtcctc 
 
 
p53Ex4F tgaggacctggtcctctgac 413 
p53Ex4R agaggaatcccaaagttcca 
 
 
p53Ex5-6F tgttcacttgtgccctgact 467 
P53Ex5-6R ataacccctcctcccagaga 
 
 
p53Ex7F cttgccacaggtctccccaa 263 
P53Ex7R aggggtcagaggcaagcaga 
 
 
p53Ex8-9F ttgggagtagatggagcct 445 
P53Ex8-9R agtgttagactggaaacttt 
 
 
p53Ex10F caattgtaacttgaaccatc 260 
P53Ex10R ggatgagaatggaatcctat 
 
 
p53Ex11F agaccctctcactcatgtga 245 
P53Ex11R tgacgcacacctattgcaag  
 
DNA was extracted from deparaffinized tissue 
sections in polypropylene tubes using Dynabeads 
DNA kit (Invitrogen, ThermoFisher Scientific). 
Evaluation of the quality and quantity of the 
isolated material was made using horizontal agarose 
gel electrophoresis and spectrophotometer (Thermo 
Scientific Evolution 260 Bio spectrophotometer). 
 
Polymerase Chain Reaction (PCR) 
For amplification of the DNA regions of 
interest, standard polymerase chain reaction was 
performed. The PCR reaction was performed on 
AutoQ server thermal cycler (Quanta Biotech).  
 
Detection of TP53 gene mutations 
Detection of TP53 gene mutations in the 
amplified exons was carried out with Sanger DNA 
sequencing on automated genetic analyser ABI 310 
Genetic Analyzer (Applied Biosystems®). 
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Sequencing of the amplified DNA fragment 
The technique of DNA sequencing was 
performed using the commercial Big Dye Terminator 
v.1.1 Cycle Sequencing Kit. Two μl of the PCR 
product were used to perform the sequencing 
reaction, 2 μl of 2.5 X Big Dye Terminator v.1.1 Cycle 
Sequencing, 1 μl 5 X Big Dye Sequencing Buffer and 
1 μl of 10 pmol forward or reverse primer in a total 
volume of 10 μl. 
After the sequencing reactions competed, 
capillary gel electrophoresis of the purified mixture 
was performed on automated genetic analyser ABI 
310 under the conditions of the 
BDx_Standard_Seq_Assay_POP4 module. The 
electrophoresis products were subsequently analysed 
with the protocol KB_310_POP4_BDTv1.1 through 
the software Sequencing Analysis v5.4 and TP53 
gene mutations were confirmed through the 
SeqScape v2.7 software. 
 
 
Results 
 
Ten patients out of 30 (33.33%) were female, 
and 20 (66.66%) were male, aged 38 to 76, with a 
mean age of 59.13 years. Twenty-three patients 
(76.66%) were serologically positive for hepatitis B, 
two patients (6.6%) were seropositive for hepatitis C, 
and 5 (16.66%) patients were seronegative to both B 
and C hepatitis. Liver cirrhosis was detected in 28 
(93.33%) patients. In the most of the patients the local 
growth was determined as T2 - 13 cases (43.33%), in 
5 (16.66%) patients the local growth was determined 
as T1, in 10 (33.33%) patients it was T3 and one 
patient (3.33%) had T4 status of the local growth. 
Vascular invasion was detected in 20 (66.66%) 
patients. Six patients (20%) had multiple HCC nodes 
in the liver, and the remainder 10 patients (33.33%) 
had solitary tumours. The smallest tumour node 
measured 3.5 cm and largest 16 cm. 
Clinicopathological characteristics of the analysed 
group of patients and immunoexpression of p53 in 
HCC tissue are shown in Table 2. 
Immunohistochemical staining with the 
antibody against p53 showed positivity in the range 
from 0% to 90% in the cell nuclei (Figure1). Changes 
in p53 gene sequence were detected in four patients 
(13.33%), but one of them a polymorphism, and the 
other three were missense point mutations. So, p53 
gene mutation was found in 3 (10%) out of 30 
patients, highlighted in Table 2, under the numbers 
10, 20, and 21. 
All 3 mutations were heterozygous point 
mutations, in exon 7. No mutations were found in 
codon 249. The polymorphism in codon 247 (exon 7) 
was detected in patient 7. Missense point mutations in 
codon 260 (exon 7) was detected in patient 10, in 
codon 245 (exon 7) in patient 20, and in codon 242 
(exon 7) in patient 21 (Figure 2). 
Two patients with missense mutations were 
male, and one was female at the age of 38 to 75 
years, mean 60.66 years. Two of the patients had 
hepatitis B infection, and one was negative. All 
patients had cirrhosis and solitary tumours ranging in 
size from 2.5 cm to 16 cm. All showed the presence of 
vascular invasion. Two of the tumours were 
moderately differentiated; one was well differentiated. 
Two of them showed a T2 tumour local growth, and 
one was T4 tumour status. The percentage of the p53 
immunohistochemical expression ranged from 0 to 90 
per cent. 
Table 2: Clinicopathological characteristics of the patients and p53 immunoexpression 
Patient Gender Age Hepatitis  
B C 
Cirrhosis Tumour 
node 
Tumour size****  
Cm 
Vascular invasion G T Р53  
% 
Survival 
Months 
1 f* 42 + - + М*** 12 - 2 3 5 8 
2 m** 63 + - + 1 7 + 2 2 20 1 
3 m 66 + - + 1 11 + 2 2 25 26 
4 m 57 + - + М 9 + 2 3 30 21 
5 f 59 + - + 1 3.5 + 2 2 50 23 
6 m 76 + - + М 3.5 - 1 2 20 70 
7 m 65 + - + 1 3.5 + 2 2 50 13 
8 m 66 + - + 1 3.8 - 2 1 50 24 
9 f 75 - + + М 12 + 3 2 30 1 
10 f 38 + - + 1 10 + 2 4 90 12 
11 f 73 + - + 1 2.5 + 2 1 85 62 
12 m 53 + - + 1 9 + 2 2 80 1 
13 m 52 + - + 1 9 - 3 1 30 17 
14 m 56 + - + 1 3 - 1 1 25 13 
15 m 74 1 - + 1 10 + 1 1 50 13 
16 f 59 + - - 1 15 + 2 3 20 9 
17 f 71 - - + 1 10 + 1 3 80 9 
18 f 57 + - + М 10 + 2 4 70 3 
19 m 67 + - + М 6 - 1 2 90 25 
20 m 75 + - + 1 2.5 + 1 2 0 8 
21 m 69 - - + 1 16 + 2 2 0 4.5 
22 m 42 + - + 1 12 - 2 3 90 24 
23 m 61 + - + 1 10 + 1 3 80 7 
24 m 50 - + + 1 11 + 2 3 90 6 
25 m 48 + - + 1 14 - 1 2 70 6 
26 f 67 - - + 1 12 - 1 2 40 11 
27 f 48 + - + 1 10 + 3 3 1 7 
28 m 65 - - + 1 7 + 1 3 20 8 
29 m 52 + - - 1 6.5 - 1 3 10 23 
30 м 58 - - + 1 3 + 2 2 80 2 
* Female, ** Male, ***Multiple tumour nodes in the liver. **** If multiple nodes present - the greatest dimension of the greatest node is shown in the table. 
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Figure 1: Micro-image of immunohistochemical staining for p53 in 
HCC tissue. a) Negative immunostaining for p53 (patient No. 20) 
(10 x 40) b). Variable intensity of immunostaining in about 90% of 
the tumour tissue in this microscopic field. The surrounding non-
coloured tissue represents a cirrhotic tissue in which a tumour 
infiltrates (patient No. 10), (10 x 20) 
 
In tumour samples where p53 missense 
mutations in codons 245 and 242 were detected, the 
immunoexpression of p53 was 0% (cases 20 and 21), 
and the tumour sample with a p53 missense mutation 
in codon 260 (case 10) showed an immunoexpression 
of p53 in approximately 90% of the tumour cells. 
 
Figure 2: a) AAC> AGC LYS247SER (Patient 10) b) Polymorphism 
TCC> TCT SER260SER (patient7) c) GGC> GAC GLY245ASP 
(Patient 20) d) TGC> AGC CYS242SER (Patient 21) 
 
The survival time of the entire group was 1 to 
70 months, mean survival 15.25 months. Patients with 
missense mutations in p53 gene had a mean survival 
of 8.16 months (min. 4.5; max. 12), while those 
without p53 mutation had a mean survival time of 16 
months (min. 1; max. 70; SD = 16.58). However, 
intergroup differences were insignificant (P > 0.05), 
probably due to the small number of cases in the 
group with mutated p53.  
 
 
Discussion 
 
The p53 gene is located on the 17th 
chromosome (17p13.1) and encodes phosphoprotein, 
formed by 393 amino acids. It consists of 4 units 
(domains): a) a domain that activates transcription 
factors, b) a domain that recognises specific DNA 
sequences, c) a domain responsible for 
tetramerisation of the protein, and d) a domain that 
recognises damaged DNA. The protein responds to 
different cellular stresses to regulate the expression of 
target genes, thereby induces cell cycle arrest, 
apoptosis, ageing, DNA repair, or changes in 
metabolism [20] [ 21]. 
The level of p53 protein in normal cells is low, 
and the wild type of p53 is a labile protein. Cellular 
stress can trigger a rise in the p53 protein to fulfil its 
function as a "genome keeper" [20] [21] [22]. 
P53 gene mutations are the most commonly 
reported somatic mutations in human neoplasms. 
Reports have been published in which mutations in 
the p53 gene, or positive immunostaining for p53, are 
associated with a higher grade of neoplasms and a 
more advanced stage in various types of malignant 
tumours. In many reports p53 mutations are 
considered a strong marker that predicts an increased 
risk of local relapse, failure of therapy and poor 
survival in many types of human neoplasms, such as 
breast cancer [24], colorectal cancer [25], cancer of 
esophagus [26], lung [27], ovarian cancer [28] and 
head and neck cancer [29]. 
Several studies suggest that p53 mutations 
are involved in determining the differentiation, 
proliferative activity, and progression of the HCC. p53 
mutations are also associated with marked HCC 
invasiveness and may influence the postoperative 
course and occurrence of relapses [20] [21] [22] [23]. 
Additionally, p53 mutations or overexpression of the 
mutant p53 protein can be used as a significant 
indicator of a poor prognosis [30] [31] [32] [33] [34] 
[35] [36]. However, for the predictive evaluation of 
HCC, the p53 effect should be considered in 
correlation with other significant factors such as 
tumour size, Child-Pugh score, TNM stage and 
vascular invasion [14]. 
Positive immunoexpression of the mutant p53 
protein is detected in 37% HCC, but the 
overexpression of the p53 protein does not always 
depend on the p53 mutation [37] [38] [39]. 
Hence, mutations in the p53 gene in patients 
with HCC, in each case are of particular importance, 
especially for the development of new modalities of 
therapy and the application of gene therapy. Today's 
therapy for patients with HCC is with limited efficacy. 
The development of gene therapy for HCC, such as 
the use of apoptotic genes, genes that code anti-
angiogenic factors or immunomodulatory molecules, 
gives hope for a longer survival of patients with HCC 
[15] [16] [17] [18]. 
In this study, three mutations of the p53 gene 
were found in three different patients out of 30 
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analysed. In two of the tumour samples with a p53 
missense mutation, we did not find any 
immunoexpression of the p53 protein, although the 
mutation was present. In the third case, the 
immunoexpression of the pathological p53 was 90% 
of cells. 
The survival time of patients with confirmed 
mutations in this study was shorter than the survival 
time of the remaining patients, however statistically 
insignificant (P > 0.05). So, the detection of the mutant 
p53 gene is necessary for each patient with HCC, to 
build a strategy for application of appropriate therapy. 
Detection of mutations in the p53 gene in 
survivors will also provide a gene therapy option with 
p53 products already in commercial use or in 
development [15] [16] [17] [18]. 
 
 
Compliance with Ethical Standards 
  
All procedures performed in studies involving 
human participants were by the ethical standards of 
the institutional and/or national research committee 
and with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards. 
Informed consent was obtained from all individual 
participants included in the study. 
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